Mechanistic considerations for the use of monoclonal antibodies for cancer therapy

Cancer Biology and Medicine

Volumn 11, Issue 1, 2014, Pages 20-33

  Glassman, Patrick M ^a   Balthasar, Joseph P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antibodies; Monoclonal; Oncology; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CELL SURFACE RECEPTOR; CETUXIMAB; DENOSUMAB; ELOTUZUMAB; FARLETUZUMAB; IBRITUMOMAB TIUXETAN; INOTUZUMAB OZOGAMICIN; IPILIMUMAB; MONOCLONAL ANTIBODY; MOXETUMOMAB PASUDOTOX; NAPTUMOMAB ESTAFENATOX; NECITUMUMAB; NIVOLUMAB; OFATUMUMAB; ONARTUZUMAB; OZOGAMICIN; PANITUMUMAB; PERTUZUMAB; RACOTUMOMAB; RILOTUMUMAB; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VASCULOTROPIN; VEDOTIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; CANCER IMMUNOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG BINDING; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENDOCYTOSIS; HUMAN; INTRACELLULAR SIGNALING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; TARGET MEDIATED DRUG DISPOSITION;

EID: 84897933951     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2014.01.002     Document Type: Review

References (99)

1. Hericourt J, Richet C. Physologie Pathologique-de la serotherapie dans la traitement du cancer. Comptes Rendus Hebd. Seanc Acad Sci 1895;121:567-569.
2. Ehrlich P, eds. Collected Studies on Immunity. New York: John Wiley & Sons; 1906.
3. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-497.
4. Smith M R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-7368.
5. Hudis C A. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
6. Alinari L, Lapalombella R, Andritsos L, Baiocchi R A, Lin T S, Byrd J C. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007;26:3644-3653.
7. Srinivasan A, Mukherji S K. Tositumomab and iodine I 131 tositumomab (Bexaar). AJNR Am J Neuroradiol 2011;32:637-638.
8. Zhuang H, Xue Z Y, Wang L, Li X Y, Zhang N, Zhang R X. Efficacy and Immune Mechanisms of Cetuximab for the Treatment of Metastatic Colorectal Cancer. Clin Oncol Cancer Res 2011;8:207-214.
9. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7:335-345.
10. Schneider-Merck T, Lammerts van Bueren J J, Berger S, Rossen K, van Berkel P H, Derer S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010;184:512-520.
11. Nightingale G. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. Ann Pharmacother 2011;45:1248-1255.
12. Lipson E J, Drake C G. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011;17:6958-6962.
13. Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini K S, Sotiriou C, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol 2013;24:273-282.
14. Junttila T T, Li G, Parsons K, Phillips G L, Sliwkowski M X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011;128:347-356.
15. Reichert J M. Antibodies to watch in 2013: Mid-year update. Mabs 2013;5:513-517.
16. van Rhee F, Szmania S M, Dillon M, van Abbema A M, Li X, Stone M K, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 2009;8:2616-2624.
17. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
18. Habermann T M, Weller E A, Morrison V A, Gascoyne R D, Cassileth P A, Cohn J B, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.
19. Waldmann T A, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969;13:1-110.
20. Wang W, Wang E Q, Balthasar J P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84:548-558.
21. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994;56:248-252.
22. Mager D E, Jusko W J. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001;28:507-532.
23. Meijer R T, Koopmans R P, ten Berge I J, Schellekens P T. Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen. J Pharmacol Exp Ther 2002;300:346-353.
24. Jain R K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50:814s-819s.
25. Fujimori K, Covell D G, Fletcher J E, Weinstein J N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31:1191-1198.
26. Juweid M, Neumann R, Paik C, Perez-Bacete M J, Sato J, van Osdol W, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992;52:5144-5153.
27. Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993;53:4322-4328.
28. Steplewski Z, Lubeck M D, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 1983;221:865-867.
29. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-758.
30. Paul WE, eds. Fundamental immunology. Philadelphia: Lippincott Williams & Wilkins; 2003.
31. Capone P M, Papsidero L D, Croghan G A, Chu T M. Experimental tumoricidal effects of monoclonal antibody against solid breast tumors. Proc Natl Acad Sci U S A 1983;80:7328-7332.
32. Brüggemann M, Williams G T, Bindon C I, Clark M R, Walker M R, Jefferis R, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166:1351-1361.
33. Trauth B C, Klas C, Peters A M, Matzku S, Möller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-305.
34. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003;3:939-951.
35. Tacke M, Hanke G, Hanke T, Hünig T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 1997;27:239-247.
36. Suntharalingam G, Perry M R, Ward S, Brett S J, Castello-Cortes A, Brunner M D, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355:1018-1028.
37. Gerber H P, Koehn F E, Abraham R T. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep 2013;30:625-639.
38. Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 2012;29:2354-2366.
39. Trail P A, Willner D, Lasch S J, Henderson A J, Hofstead S, Casazza A M, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993;261:212-215.
40. Tolcher A W, Sugarman S, Gelmon K A, Cohen R, Saleh M, Isaacs C, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 1999;17:478-484.
41. Shah N N, Bhojwani D, Silverman L B, Whitlock J A, Richards K, Stetler-Stevenson M, et al. A novel anti-CD22 immunotoxin, moxetumomab pasudotox (Ha22, Cat-8015): activity in pediatric patients with relapsed acute lymphoblastic leukemia (All) after allogeneic hematopoietic stem cell transplantation (Sct). Biol Blood Marrow Tr 2012;18:S234-S234.
42. Vitetta E S, Stone M, Amlot P, Fay J, May R, Till M, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991;51:4052-4058.
43. Sharkey R M, Press O W, Goldenberg D M. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood 2009;113:3891-3895.
44. Mould D R, Baumann A, Kuhlmann J, Keating M J, Weitman S, Hillmen P, et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007;64:278-291.
45. Hillmen P, Skotnicki A B, Robak T, Jaksic B, Dmoszynska A, Wu J, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-5623.
46. Lozanski G, Heerema N A, Flinn I W, Smith L, Harbison J, Webb J, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-3281.
47. Lu J F, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008;62:779-786.
48. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
49. Younes A, Bartlett N L, Leonard J P, Kennedy D A, Lynch C M, Sievers E L, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-1821.
50. Pro B, Advani R, Brice P, Bartlett N L, Rosenblatt J D, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190-2196.
51. Younes A, Gopal A K, Smith S E, Ansell S M, Rosenblatt J D, Savage K J, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-2189.
52. Tan A R, Moore D F, Hidalgo M, Doroshow J H, Poplin E A, Goodin S, et al. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 2006;12:6517-6522.
53. Bonner J A, Harari P M, Giralt J, Azarnia N, Shin D M, Cohen R B, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
54. Karapetis C S, Khambata-Ford S, Jonker D J, O'Callaghan C J, Tu D, Tebbutt N C, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765.
55. Gibiansky L, Sutjandra L, Doshi S, Zheng J, Sohn W, Peterson M C, et al. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet 2012;51:247-260.
56. Stopeck A T, Lipton A, Body J J, Steger G G, Tonkin K, de Boer R H, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-5139.
57. Witzig T E, Gordon L I, Cabanillas F, Czuczman M S, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-2463.
58. Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs 2011;71:1093-1104.
59. Hodi F S, O'Day S J, McDermott D F, Weber R W, Sosman J A, Haanen J B, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
60. Phan G Q, Yang J C, Sherry R M, Hwu P, Topalian S L, Schwartzentruber D J, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-8377.
61. Coiffier B, Losic N, Rønn B B, Lepretre S, Pedersen L M, Gadeberg O, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. Br J Haematol 2010;150:58-71.
62. Wierda W G, Kipps T J, Mayer J, Stilgenbauer S, Williams C D, Hellmann A, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-1755.
63. Czuczman M S, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 2012;119:3698-3704.
64. Yang B B, Lum P, Chen A, Arends R, Roskos L, Smith B, et al. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet 2010;49:729-740.
65. Freeman D J, McDorman K, Ogbagabriel S, Kozlosky C, Yang B B, Doshi S, et al. Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Mol Cancer 2012;11:47.
66. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
67. Amado R G, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D J, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
68. Ng C M, Lum B L, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006;23:1275-1284.
69. Baselga J, Cortés J, Kim S B, Im S A, Hegg R, Im Y H, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 2012;366:109-119.
70. Berinstein N L, Grillo-López A J, White C A, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995-1001.
71. Maloney D G, Grillo-López A J, White C A, Bodkin D, Schilder R J, Neidhart J A, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-2195.
72. BEXXAR (package insert) (2013) Glaxo-Smith-Kline, Research Triangle Park, NC.
73. Kaminski M S, Zelenetz A D, Press O W, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-3928.
74. ® therapeutic regimen (tositumomab and iodine I 131 tositumomab). Press Release. August 7, 2013.
75. Bruno R, Washington C B, Lu J F, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005;56:361-369.
76. Lee C M, Tannock I F. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer 2010;10:255.
77. Slamon D J, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
78. Girish S, Gupta M, Wang B, Lu D, Krop I E, Vogel C L, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012;69:1229-1240.
79. Verma S, Miles D, Gianni L, Krop I E, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-1791.
80. Burris H A 3rd, Rugo H S, Vukelja S J, Vogel C L, Borson R A, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405.
81. Zonder J A, Mohrbacher A F, Singhal S, van Rhee F, Bensinger W I, Ding H, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012;120:552-559.
82. Lonial S, Vij R, Harousseau J L, Facon T, Moreau P, Mazumder A, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012;30:1953-1959.
83. Armstrong D K, White A J, Weil S C, Phillips M, Coleman R L. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 2013;129:452-458.
84. Eisai announces results of phase III study of anticancer agent farletuzumab in patients with relapsed platinum-sensitive ovarian cancer. Press Release. January 11, 2013.
85. Ogura M, Hatake K, Ando K, Tobinai K, Tokushige K, Ono C, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci 2012;103:933-938.
86. Ogura M, Tobinai K, Hatake K, Uchida T, Kasai M, Oyama T, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci 2010;101:1840-1845.
87. Pfizer discontinues phase 3 study of inotuzumab ozogamicin in relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) due to futility. Press Release. May 20, 2013.
88. Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013;119:2728-2736.
89. Kreitman R J, Tallman M S, Robak T, Coutre S, Wilson W H, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012;30:1822-1828.
90. Kreitman R J, Arons E, Stetler-Stevenson M, Wilson W H, FitzGerald D J, Pastan I. Pharmacokinetic analysis of response in hairy cell leukemia treated by anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Blood 2013;122:2871.
91. Forsberg G, Skartved N J, Wallén-Ohman M, Nyhlén H C, Behm K, Hedlund G, et al. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother 2010;33:492-499.
92. Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, et al. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:4116-4123.
93. Kuenen B, Witteveen P O, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, et al. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 2010;16:1915-1923.
94. Lilly announces phase III necitumumab study meets primary endpoint of overall survival. Press Release. August 13, 2013.
95. Kuenen B, Witteveen P O, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, et al. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 2010;16:1915-1923.
96. Wolchok J D, Kluger H, Callahan M K, Postow M A, Rizvi N A, Lesokhin A M, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-133.
97. Xin Y, Jin D, Eppler S, Damico-Beyer L A, Joshi A, Davis J D, et al. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. J Clin Pharmacol 2013;53:1103-1111.
98. Neninger E, Díaz R M, de la Torre A, Rives R, Díaz A, Saurez G, et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 2007;6:145-150.
99. Gordon M S, Sweeney C S, Mendelson D S, Eckhardt S G, Anderson A, Beaupre D M, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010;16:699-710.